EU approves Illumina’s plan to divest cancer test maker Grail By Reuters
By Foo Yun Chee BRUSSELS (Reuters) -U.S. gene sequencing company Illumina (NASDAQ:)'s plan to divest cancer diagnostic test maker Grail ...
By Foo Yun Chee BRUSSELS (Reuters) -U.S. gene sequencing company Illumina (NASDAQ:)'s plan to divest cancer diagnostic test maker Grail ...
© Reuters. FILE PHOTO: A sign at the front entrance to the global headquarters of Illumina is pictured in San ...
Sundry Photography/iStock Editorial via Getty Images Illumina's (NASDAQ:ILMN) planned $7.1 billion purchase of cancer test developer Grail was sent back ...
© Reuters. An Illumina office building is shown in San Diego, California, U.S.,October 20, 2023. REUTERS/Mike Blake/File photo By Diane ...
Sundry Photography/iStock Editorial via Getty Images Illumina (NASDAQ:ILMN) faces a record fine from the European Union as early as next ...
© Reuters. (Reuters) -Cancer test maker Grail Inc said on Friday that its telemedicine vendor erroneously sent letters to about ...
© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.
© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.